The call, up front. Demand for GLP-1 (the class of weight-loss and diabetes drugs like Ozempic) was never going to be limited by the supply of the molecule. It was going to be limited by sterile fill-finish: the germ-free step of loading the drug into an auto-injector (the pen-style device patients inject with). Peptide synthesis (making the drug molecule itself) scaled on schedule; the real blocker slid downstream, to a later step: the thick (high-viscosity), device-ready sterile fill, held by a handful of contract manufacturers. That intersection was visible long before investors repriced it.
The gap
Everyone modelled the demand curve. Almost nobody modelled the constraint moving. The molecule scaled on plan; the squeeze slid to the one step that couldn’t scale up with it: sterile, device-ready fill-finish, where the wait for new equipment runs 18–24 months and a handful of CDMOs hold the capacity.
Model the blocking step, not the headline molecule. Money aimed at API plants was solving a problem that was already solved; the contracts that mattered were for fill-finish lines.
Source: Eli Lilly Q4 financial releases, FY2023–FY2025
Eli Lilly incretin franchise (Mounjaro + Zepbound) global revenue, $B, from Lilly Q4 financial press releases FY2023–FY2025; 2022 (~$0.5bn, Mounjaro's launch year) is approximate. The constraint is built-in, not temporary: sterile fill-finish and auto-injector assembly equipment carry 18–24-month lead times, so the step cannot scale with demand.
Source: GAPTIQ engine: challenge decomposition
- Feb 2024Novo Holdings agrees to buy Catalent for $16.5B, a move to lock up fill-finish capacity
- Dec 2024Deal closes; three sterile fill-finish sites transfer to Novo Nordisk
- Dec 2024FDA declares the tirzepatide (Mounjaro/Zepbound) shortage resolved
- Feb 2025FDA resolves the semaglutide (Ozempic/Wegovy) shortage, ending a roughly three-year squeeze
Source: Novo Holdings; FDA drug shortage database, 2024–2025
The molecule was never the constraint. The capacity to put it in a syringe was.
GAPTIQ Signal · Mar 2026
The move
The point is not that the bottleneck became obvious: it is that the intersection was visible eighteen months earlier, in filings, capex disclosures and FDA records that were public the whole time. For an operator (a company actually making and shipping the drug), the move was to lock in fill-finish capacity-as-a-service (renting production slots instead of building your own) while it was still a weak signal. By the time it was a headline, the contracts were gone.
Source: Novo Nordisk Annual Report 2024, Novo Nordisk A/S, 2025; FDA Declaratory Order resolving the semaglutide shortage, Feb 2025. Surfaced by the GAPTIQ engine.
